Govt engaging with drug makers to ramp up production of anti-fungal drug

The government is engaging with the drug manufacturers to ramp up the production of an antifungal drug used for the treatment of mucormycosis, says Chemicals and Fertilizers Ministry

Topics

Coronavirus | central government | Drug makers in India

The government is engaging with the drug manufacturers to ramp up the production of an antifungal drug used for the treatment of mucormycosis, the Chemicals and Fertilizers Ministry said, as a rash of cases of rare black fungus infection have been reported among people either recovered or recovering from COVID-19.

With a spike in the cases of COVID-19 in the country, doctors have been reporting a rare infection mucormycosis, also called as black fungus, among people recovered from COVID-19. The infection is caused by exposure to mucor mould and it affects the sinuses, the brain and the lungs and can be life-threatening.

“A sudden increase in demand has been observed in some states for Amphotericin B which is being actively prescribed by the physicians to patients suffering from mucormycosis, a post-COVID complication,” the ministry said in a statement.

The government is therefore engaging with the manufacturers to ramp up production of the drug. The supply position is expected to improve with extra imports of this drug and increase in its production domestically, it added.

“After reviewing the stock position with the manufacturers/importers, and the demand pattern of Amphotericin B, the Department of Pharma, has on 11th May, 2021 , allocated this drug amongst the States/UTs based on expected supply that will be available from May 10 to May 31, 2021,” the statement said.

States have been requested to put in place a mechanism for equitable distribution of supplies amongst government and private hospitals and health care agencies, it added.

States have also been requested to publicise in the state the ‘Point of Contact’ for private and government hospitals to obtain the drug from this allocation, the statement said.

“The arrangements for supply will be monitored by the National Pharmaceuticals Pricing Authority (NPPA),” it added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.


We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor